Merck & Co. $MRK has reportedly entered discussions to acquire Swiss biotech firm MoonLake Immunotherapeutics $MLTX in a deal exceeding $3 billion, according to sources cited by the Financial Times. This potential acquisition underscores a broader industry trend where big pharma firms target clinical-stage biotech companies with promising late-stage assets to boost their immunology and specialty drug pipelines.